T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial

Hertz, Tomer; Gartland, Andrew J.; Janes, Holly; Li, S; Fong, Youyi; Tomaras, GD; Morris, Daryl E.; Geraghty, Daniel E.; Kijak, GH; Edlefsen, PT; Rolland, Morgane; Larsen, BB; Tovanabutra, Sodsai; Sanders‐Buell, Eric; Ac, deCamp; Magaret, CA; Ahmed, Hasan; Nariya, Snehal; Wong, Kim; Zhao, Hong; Deng, Wenjie; Maust, BS; Bose, Meera; Howell, Shana; Lazzaro, Michelle; Bates, Adam; Lei, Esther; Bradfield, Andrea; Ibitamuno, Grace; Assawadarachai, Vatcharain; O'Connel, RJ; deSouza,; Nitayaphan, Sorachai; Rerks-Ngarm, Supachai; Robb, ML; McElrath, M. Juliana; Haynes, BF; Michael, NL; Gilbert, P; Mullins, JI; Kim, Jae‐Hun

doi:10.1186/1742-4690-9-s2-o61

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is speculated that vaccine-induced responses may have hindered HIV-1 infection with 181 variants, other explanations including involvement of other unidentified sequences near position 181 or inability of this variant to establish infection due to steric hindrance with vaccine-induced antibodies. The assessment of a T-cell based sieve effect in envelope V1/V2 revealed an association between an HLA class I allele and VE, suggesting that VE was restricted to A*02(+) participants and that IgA-C1 antibodies inhibited protective effects of other responses in A*02(−) participants [ 25 ].…”

Section: Opportunitiesmentioning

confidence: 99%

An HIV Vaccine for South-East Asia—Opportunities and Challenges

et al. 2013

View full text Add to dashboard Cite

Recent advances in HIV vaccine development along with a better understanding of the immune correlates of risk have emerged from the RV144 efficacy trial conducted in Thailand. Epidemiological data suggest that CRF01_AE is still predominant in South-East Asia and is spreading in China with a growing number of circulating recombinant forms due to increasing human contact, particularly in large urban centers, tourist locations and in sites of common infrastructure. A vaccine countering CRF01_AE is a priority for the region. An Asia HIV vaccine against expanding B/E or BCE recombinant forms should be actively pursued. A major challenge that remains is the conduct of efficacy trials in heterosexual populations in this region. Men who have sex with men represent the main target population for future efficacy trials in Asia. Coupling HIV vaccines with other prevention modalities in efficacy trials might also be envisaged. These new avenues will only be made possible through the conduct of large-scale efficacy trials, interdisciplinary teams, international collaborations, and strong political and community commitments.

show abstract

Section: Opportunitiesmentioning

confidence: 99%

An HIV Vaccine for South-East Asia—Opportunities and Challenges

et al. 2013

View full text Add to dashboard Cite

show abstract

“…One way to assess the credibility of the immune system is linked to the analysis of the HIV-infected participants in the test sequence using a sieve analysis method [73][74][75][76][77][78][79]. Because this approach to assess the impact of the vaccine from the viewpoint of viruses penetrating injury, because they represent the other side of the coin of the associated immune response.…”

Section: Step Studymentioning

confidence: 99%

Efficacy Trials and Progress of HIV Vaccines

Asif¹,

Irshad²

2017

J Cell Sci Ther

View full text Add to dashboard Cite

Discovery of HIV as causative agent of AIDS let to the belief that a vaccine for AIDS will be available shortly but was not that easy, and it took more than 30 years of hard laboratory and clinical work toward HIV vaccine development. Efficacy trials of RV144 and their results revealed that HIV vaccine is accomplishable. Clinical trials for developing bNAbs has monoclonal antibodies and to increase its half-life are also underway to achieve a proper HIV vaccine. In this review article, we see that how these efficacy trials are highlighting HIV vaccine concepts in clinical development. Therapeutic vaccines are proving to be a functional cure toward HIV treatment and progress is ongoing in such HIV vaccine development which will attack HIV before it fuses with cell and cause infection thus preventing AIDS. So, in near future it will be possible to cure HIV and bring an end to this epidemic.

show abstract

Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates

Tomaras¹,

Haynes²

2013

Vaccines

View full text Add to dashboard Cite

Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine clinical trials have provided hypotheses regarding the mechanisms of induction of protective immunity to HIV-1. To date, there have been six HIV-1 vaccine efficacy trials (VAX003, Vaxgen, Inc., San Francisco, CA, USA), VAX004 (Vaxgen, Inc.), HIV-1 Vaccine Trials Network (HVTN) 502 (Step), HVTN 503 (Phambili), RV144 (sponsored by the U.S. Military HIV Research Program, MHRP) and HVTN 505). Cellular, humoral, host genetic and virus sieve analyses of these human clinical trials each can provide information that may point to potentially protective mechanisms for vaccine-induced immunity. Critical to staying on the path toward development of an efficacious vaccine is utilizing information from previous human and non-human primate studies in concert with new discoveries of basic HIV-1 host-virus interactions. One way that past discoveries from correlate analyses can lead to novel inventions or new pathways toward vaccine efficacy is to examine the intersections where different components of the correlate analyses overlap (e.g., virus sieve analysis combined with humoral correlates) that can point to mechanistic hypotheses. Additionally, differences in durability among vaccine-induced T- and B-cell responses indicate that time post-vaccination is an important variable. Thus, understanding the nature of protective responses, the degree to which such responses have, or have not, as yet, been induced by previous vaccine trials and the design of strategies to induce durable T- and B-cell responses are critical to the development of a protective HIV-1 vaccine.

show abstract

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial

Cited by 3 publications

References 0 publications

An HIV Vaccine for South-East Asia—Opportunities and Challenges

An HIV Vaccine for South-East Asia—Opportunities and Challenges

Efficacy Trials and Progress of HIV Vaccines

Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates

Contact Info

Product

Resources

About